hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma

In recent years, new treatment options for malignant melanoma patients have enhanced the overall survival for selected patients. Despite new hope, most melanoma patients still relapse with drug-resistant tumors or experience intrinsic resistance to the therapy. Therefore, novel treatment modalities...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleten, Karianne G, Flørenes, Vivi Ann, Prasmickaite, Lina, Hill, Oliver, Sykora, Jaromir, Mælandsmo, Gunhild M, Engesæter, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149582/
https://www.ncbi.nlm.nih.gov/pubmed/28028438
http://dx.doi.org/10.1038/cddiscovery.2016.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149582/
https://www.ncbi.nlm.nih.gov/pubmed/28028438
http://dx.doi.org/10.1038/cddiscovery.2016.81

Ejemplares similares